Naprod Life Sciences announced that it will exhibit at CPHI South East Asia 2026, held 8–10 July 2026 in Bangkok, Thailand, at Booth B31. According to the company’s own announcement, Naprod will showcase its expertise in oncology, injectable, and lyophilized (freeze-dried) formulations, and invites visitors to explore strategic partnerships and manufacturing capabilities at the stand.
CPHI South East Asia is a regional edition of the CPHI series of pharmaceutical trade exhibitions, which bring together manufacturers, contract-development and manufacturing organizations, ingredient suppliers, and distributors from across the pharmaceutical supply chain.
Why it matters
Trade exhibitions such as CPHI are a primary channel through which an export-oriented manufacturer meets distributors and licensing partners for new markets. Naprod’s presence at the South East Asia edition aligns with the registration pathways it is pursuing across the region, including markets that recognize WHO-GMP and PIC/S-aligned authorities, and with its sterile oncology and lyophilized injectable product lines manufactured at Tarapur.
This is a company announcement, published on Naprod’s official LinkedIn page, and is presented here as such, not as an independently verified news report. Distributors and partners planning to attend can confirm booth details directly with the company.